Vital blue dyes were used to show the feasibility and accuracy of intraoper
ative lymphatic mapping of the sentinel node (SN) in patients with melanoma
, breast cancer, and other solid tumors. Surgeons who have successfully com
pleted an adequate number of cases of intraoperative mapping and sentinel l
ymph node dissection (SLND) can use blue dye alone to localize the SN. Howe
ver, radiopharmaceutical agents can facilitate intraoperative mapping; preo
perative lymphoscintigraphy can identify the location of the SN, and intrao
perative mapping with the gamma probe can provide an auditory signal that c
omplements the visual guide provided by the blue dye, Studies are required
to establish more clearly the intralymphatic kinetics of the various radiop
harmaceutical agents. An ongoing international Phase III trial in melanoma,
the 2 upcoming trials in breast cancer, and similar trials for other solid
tumors will further clarify the future role of SLND. Copyright (C) 2000 by
W.B. Saunders Company.